Pagina 55 - I migliori medici in Turchia — Richiedi una consulenza online

Dr. Mehmet Tonge is a neurosurgeon with expertise in Stereotactic and Functional Neurosurgery. He specializes in MR Guided Focused Ultrasound, deep brain stimulation, Gamma Knife Radiosurgery, and surgery for movement disorders, pain, and spasticity.

Dr. Tonge has published 32 articles in international and national journals and written 12 book chapters. He has presented 92 oral and poster presentations and delivered 41 invited lectures. He completed a Deep Brain Stimulation Fellowship at Maastricht University and finished the 4-year EANS training cycle. Dr. Tonge is known for his research and clinical work in functional neurosurgery.

Experiences

Istanbul University, Cerrahpasa Faculty of Medicine 2007-2013

Ondokuz Mayis University, Faculty of Medicine 2014-2022

Istanbul University-Cerrahpasa, Cardiology Institute 2022

Schools / Trainings

Trakya University, Faculty of Medicine, L11an1 2001-2007

Istanbul University, Cerrahpasa Faculty of Medicine, Specialization 2007-2013

Aortic Dilation (Aneurysm)

Heart Valve Problems

Aortic Dissection

Coronary Artery Disease

Carotid Artery Occlusion (Carotid Stenosis)

Varicose Veins

Peripheral Vascular Disease

Aortic Insufficiency

Aortic Valve Diseases

Mitral Insufficiency

Mitral Valve Problem

Mitral Stenosis

Varicose Ulcer

Diabetic Foot

Deep Vein Thrombosis (DVT)

Raynaud's Disease

Rheumatic Heart Disease

Ischemic Heart Disease

Heart Pain

Leg Artery Occlusion

Capillary Rupture

Heart Failure

Abdominal Aortic Aneurysm

Aortic Arch Aneurysm

Ascending Aortic Aneurysm

Thoracoabdominal Aortic Aneurysm

Carotid

In 2007, I graduated from Trakya University, Faculty of Medicine and received the title of “Medical Doctor”. In the same year, as a result of the TUS exam I took, I started my specialization training at Istanbul University, Cerrahpaşa Faculty of Medicine, Department of Cardiovascular Surgery.

During my specialization training, in 2010, I worked as a guest doctor at “Lenox Hill Hospital, Aortic Wellness Center” in New York, USA, on aortic valve-preserving surgery, aortic root surgery, aortic arch surgery, thoracoabdominal aortic surgery and robotic heart surgery.

In 2013, I worked as a “fellow” at the “Landeskrankenhaus Salzburg, Paracelsus Universitätsklinik für Gefäßchirurgie und endovaskuläre Chirurgie” clinic in Salzburg, Austria, and conducted studies on endovascular and advanced vascular surgery techniques.

In 2013, I worked as a visiting physician at the “Vita-Salute University, Scientific Institute, Ospedale San Raffaele, dipartimento di chirurgia vascolare ed endovascolare” clinic in Milan, Italy, on endovascular techniques, advanced vascular techniques and surgical treatment of thoracoabdominal aortic aneurysms.

In 2013, I completed my assistant training and earned the title of “Cardiovascular Surgery Specialist”.

As of 2014, I started working as a “Specialist Doctor” at the Department of Cardiovascular Surgery, Faculty of Medicine, Ondokuz Mayıs University.

In 2016, I received the title of “Assistant Professor Doctor”. In the same year, I received the “Certificate of Proficiency” issued by the “Turkish Cardiovascular Surgery Qualification Board”.

In 2017, I worked as a visiting doctor for 3 months at the “Landeskrankenhaus Nürnberg, Paracelsus Universitätsklinik für Gefäßchirurgie und endovaskuläre Chirurgie” clinic in Nuremberg, Germany, on advanced endovascular (FEVAR, BEVAR, CHEVAR, EVAR, TEVAR) techniques in aortic diseases.

I received the title of “Associate Professor” in 2019. I am fluent in English.

I have been working at Istanbul University-Cerrahpaşa, Cardiology Institute, Department of Cardiovascular Surgery since 2022

Dr. Atilla Ozenoglu is a thoracic surgery specialist. He completed medical school at Karadeniz University (1984–1990). He finished his thoracic surgery residency at Pamukkale University (2003–2009). He worked as a general practitioner from 1990 to 2003. He then served at Adıyaman State Hospital (2009–2014) and Gaziantep Medical Park (2014–2017). In 2017, he worked at Erzurum Regional Training and Research Hospital. He now works at Rize Recep Tayyip Erdoğan Training and Research Hospital. He serves as a thoracic surgery specialist and deputy chief physician.

Clinical expertise: lung resections (segmentectomy, lobectomy, pneumonectomy); VATS sympathectomy for hyperhidrosis; mediastinoscopy; VATS under local anesthesia; chest wall reconstruction with clip-plate implants; minimally invasive pectus surgery (Nuss, Abramson); diaphragmatic repair; diagnostic and therapeutic bronchoscopy.

Academic work: thesis “Cardiac arrhythmias after thoracotomy” (2008). Articles on non-traumatic chylothorax (2005) and primary lung liposarcoma (2009). Posters and case reports on hydatidosis serology (2012), costal osteochondroma resection (2014), and a Foley catheter imaging method in empyema necessitatis (2007).

Dr. Mehmet Orçun Akdemir is a member of the Turkish Ophthalmology Association. He has published 24 articles in international peer‑reviewed journals, many indexed in SCI/SCI‑E. He has 17 papers in national peer‑reviewed journals. He has given 5 presentations at international meetings.

His work centers on the cornea and anterior segment. Areas include keratoconus; DALK, PKP, and DSAEK; corneal biomechanics; and corneal cross‑linking. He also studies glaucoma surgery after keratoplasty, ocular surface disease and pseudoexfoliation, and neuro‑ophthalmology and retina. He contributed to 4 ophthalmology book translations. His studies compare DALK and PKP outcomes in keratoconus, analyze biomechanics after DALK, evaluate graft thickness after DSAEK, and compare trabeculectomy with the Ahmed valve in post‑PKP glaucoma.

Dr. Ibrahim Ziyal is a neurosurgeon at Memorial Göztepe Hospital in Istanbul (2025–present). He was Professor and Head of Neurosurgery at Marmara University (2012–2025). Earlier, he held faculty roles at Hacettepe University (2001–2012). He was the Founding Head of Neurosurgery at Abant İzzet Baysal University, Düzce (1999–2001). He also worked as a clinical researcher in brain tumors at George Washington University (1996–1998). He then focused on cerebrovascular diseases at the São Paulo Institute of Neurological Sciences (1998–1999).

Expertise: skull base tumors, pituitary surgery, and aneurysm/AVM/cavernoma surgery. Neurosurgery training: Şişli Etfal Hospital. MD: Trakya University. Memberships: Turkish Neurosurgical Society, Neuro-Oncology Association, AANS, CNS, WFNS, EANS.

Specializations

RIRS (Laser Stone Breaking in the Kidney)

Open-Closed Prostate Surgeries

Urological Cancer Surgeries

Urinary Incontinence Treatment

Infertility Treatment

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Specializations

Pediatric Rehabilitation of Children with Special Needs

Newborn Monitoring

Newborn and Childhood Vaccinations

Child Follow-up Monitoring and Development

Growth and Development Retardation

Childhood Diseases

Child Health and Diseases

Experience

Karadeniz Technical University Faculty of Medicine (2005)

PRIVATE TAMMED HOSPITAL

PRIVATE LIFE HOSPITAL

PRIVATE HATEM HOSPITAL

Specialist Dr. Fatih Mert Children's Clinic

Private Sevgi Hospital

Private NCR Hospital (2019-)

Çukurova University Faculty of Medicine (1994-2000)

Karadeniz Technical University (2000-2005)

Education

Çukurova University Faculty of Medicine (1994-2000)

Karadeniz Technical University Faculty of Medicine (2005)

PRIVATE TAMMED HOSPITAL

PRIVATE LIFE HOSPITAL

PRIVATE HATEM HOSPITAL

Specialist Dr. Fatih Mert Children's Clinic

Private Sevgi Hospital

Private NCR Hospital (2019-2020)

Private Center Prime (2020-2022)

Private Mercan Hospital (2022-2023)

Private BAH Hospital (2023-.....)

Professional Memberships

Newborn Intensive Care Course

Mechanical Ventilation Course

Neonatal Resuscitation Course

National Pediatrics Congress

National Pediatrics Days

Pediatrics Endocrine and Metabolism Congress

Pediatric Oncology and Hematology Congress

Asthma Symposium

Education and Specialization

• Hacettepe University Faculty of Medicine – English Medical Education
• Akdeniz University Faculty of Medicine – Internal Medicine – Residency
• Akdeniz University Hospital – Nephrology – Subspecialty Training
• San Bortolo Hospital, Vicenza, Italy – Critical Care Nephrology and Transplantation – Fellowship
• Hacettepe University Faculty of Medicine – Associate Professorship

Professional Memberships

1. Turkish Society of Nephrology (TND)
2. European Society of Nephrology (ERA-EDTA)
3. Middle East Society of Organ Transplantation (MESOT)
4. International Society of Nephrology (ISN)

Dr. Bahri Gok is a urologist at LHÜ Ankara Hospital (2024–). He earned his MD from Selçuk University (2001–2007). He completed his urology residency at Ankara Atatürk Training and Research Hospital (2008–2013). He served in the Department of Urology at Ankara Yıldırım Beyazıt University as Assistant Professor (2017–2020) and Associate Professor (2020–2023). He was the Urology Training Supervisor at Ankara City Hospital (2019–2023).

Accreditations and training include da Vinci Console Surgeon training at IRCAD (05.11.2019). He attended the EAU Robotic Urology Section meeting (2018) and the National Endourology Congresses (2013, 2015, 2019). He completed a biostatistics course (2018) and holds a Laboratory Animal Use certificate (2012). Memberships: SIU; Turkish Urology Association; Society of Urological Surgery; Eurasian Uro-oncology Association.

Achievements include serving as an investigator in a 2024 international Phase 2 trial of adjuvant V940 (mRNA‑4157) plus pembrolizumab for high‑risk muscle‑invasive urothelial carcinoma. He supervised a 2020 doctoral thesis on robot‑assisted radical prostatectomy. He received Best Poster awards at EAU (Latvia, 2015) and at the Eurasian Uro‑oncology and SIU meetings (2019).

Place and Date of Birth

• Nevşehir, 1974

Language Skills

• English

Education and Experience

• 1997 Cerrahpaşa Faculty of Medicine
• 2003 Ege University Faculty of Medicine Eye Diseases
• 2005 GATA Ankara (Military Service)
• 2018 İstanbul Training and Research Hospital (Assoc.)

National and International Publication number

• Over 50

Case Experience

• More than 20,000 surgical cases experience, 20 years of active service as an ophthalmologist

Associations

• TOD (Turkish Society of Ophthalmology)
• AAO (American Academy of Ophthalmology)

ducation and Expertise

2012 – Graduated from Necmettin Erbakan University, Meram Faculty of Medicine 

2017 – Completed specialization in Dermatology and Venereology at Yıldırım Beyazıt University, Ankara Atatürk Training and Research Hospital

Professional Experience

2012 to 2017 – Dermatology and Venereology Clinic, Ankara Atatürk Training and Research Hospital

2017 to 2019 – Tunceli State Hospital, Dermatology Department

Professional Memberships

-Turkish Dermatology Association

-Ankara Dermatology and Venereology Association

-Turkish Medical Association

Articles Published in International Peer-Reviewed Journals

A1. Akkuş A, Demirseren DD, Demirseren ME, Aktaş A.
The treatment of ingrown nail: Chemical matricectomy with NaOH versus wedge resection.
Dermatologic Therapy, 2018.

A2. Akpolat ND, Akpolat AO, Namdaroğlu O, Akkuş A.
Comparison of the Winograd method and chemical cauterization with 10% sodium hydroxide in the treatment of ingrown nails.
Turkderm, 2016.

A3. Kılınç F, Akbaş A, Şener S, Yavuz SO, Akkuş A, Aktaş A.
A case of facial lentiginous lichen planus pigmentosus associated with Hashimoto's thyroiditis and diabetes mellitus.
Our Dermatology Online, 2015.

Papers Presented at International Scientific Meetings and Published in Proceedings

B1. Akbaş A, Kılınç F, Akkuş A, Metin A, Şener S.
A retrospective analysis of hospitalized autoimmune bullous disease patients.
11th EADV Spring Symposium,  2014, Belgrade, Serbia. Abstract Program Book.

B2. Akbaş A, Kılınç F, Yavuz S, Şener S, Akkuş A, Metin A.
A rare cause of lymphedema: Morbus Morbihan disease.
23rd EADV Congress, October 2014, Amsterdam, Netherlands. Abstract Program Book, P019.

B3. Akbaş A, Kılınç F, Yavuz S, Şener S, Akkuş A, Metin A.
Rare cystic formations obstructing the external ear canal: Steatocystoma multiplex.
23rd EADV Congress, October, 2014, Amsterdam, Netherlands. Abstract Program Book, P1277.

B4. Akbaş A, Kılınç F, Şener S, Akkuş A, Özgör O, Aktaş A.
Demodicosis: Two cases.
12th EADV Spring Symposium, 2015, Valencia, Spain. Abstract Program Book, P567.

B5. Kılınç F, Akbaş A, Yavuz SO, Şener S, Akkuş A, Metin A, Demirseren DD.
A case of Paederus dermatitis.
23rd World Congress of Dermatology, 2015, Vancouver, Canada. Abstract Program Book.

B6. Akbaş A, Kılınç F, Şener S, Akkuş A, Metin A, Demirseren DD.
A case of generalized lichen amyloidosis treated with retinoids.
23rd World Congress of Dermatology, 2015, Vancouver, Canada. Abstract Program Book.

B7. Şener S, Kılınç F, Akbaş A, Yavuz HSO, Akkuş A, Metin A, Demirseren DD.
A case of acne agminata treated with isotretinoin.
23rd World Congress of Dermatology, 2015, Vancouver, Canada. Abstract Program Book.